0001193125-25-158216.txt : 20250711 0001193125-25-158216.hdr.sgml : 20250711 20250711163033 ACCESSION NUMBER: 0001193125-25-158216 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20250711 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250711 DATE AS OF CHANGE: 20250711 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Walgreens Boots Alliance, Inc. CENTRAL INDEX KEY: 0001618921 STANDARD INDUSTRIAL CLASSIFICATION: RETAIL-DRUG STORES AND PROPRIETARY STORES [5912] ORGANIZATION NAME: 07 Trade & Services EIN: 471758322 STATE OF INCORPORATION: DE FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36759 FILM NUMBER: 251119331 BUSINESS ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 BUSINESS PHONE: (847) 315-2500 MAIL ADDRESS: STREET 1: 108 WILMOT ROAD CITY: DEERFIELD STATE: IL ZIP: 60015 8-K 1 d94027d8k.htm 8-K 8-K
false 0001618921 0001618921 2025-07-11 2025-07-11 0001618921 us-gaap:CommonStockMember 2025-07-11 2025-07-11 0001618921 wba:M3.600WalgreensBootsAllianceInc.NotesDue20252Member 2025-07-11 2025-07-11 0001618921 wba:M2.125WalgreensBootsAllianceInc.NotesDue20261Member 2025-07-11 2025-07-11
 
 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 11, 2025

 

 

WALGREENS BOOTS ALLIANCE, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36759   47-1758322
(State or other jurisdiction
of incorporation)		   (Commission
File Number)		   (IRS Employer
Identification Number)

 

108 Wilmot Road, Deerfield, Illinois   60015
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (847) 315-3700

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, $0.01 par value   WBA   The Nasdaq Stock Market LLC
3.600% Walgreens Boots Alliance, Inc. notes due 2025   WBA25   The Nasdaq Stock Market LLC
2.125% Walgreens Boots Alliance, Inc. notes due 2026   WBA26   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 
 

Item 5.07.

Submission of Matters to a Vote of Security Holders.

As previously disclosed, on March 6, 2025, Walgreens Boots Alliance, Inc., a Delaware corporation (the “Company”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Blazing Star Parent, LLC, a Delaware limited liability company (“Parent”), Blazing Star Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (“Merger Sub”), and the other affiliates of Parent named therein (collectively, together with Parent and Merger Sub, the “Parent Entities”), pursuant to which, subject to the terms and conditions set forth therein, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company will cease to be a publicly traded company.

On July 11, 2025, the Company held a special meeting of stockholders (the “Special Meeting”) to consider certain proposals related to the Merger Agreement.

As of June 6, 2025, the record date (the “Record Date”) for the Special Meeting, there were 865,560,675 shares of the common stock of the Company, par value $0.01 per share (“Company Common Stock”), outstanding, each of which was entitled to one vote on each matter considered at the Special Meeting. As of the Record Date, there were 717,727,706 shares of Company Common Stock held by holders other than Stefano Pessina, John Lederer, Parent and any of their respective affiliates (the “Unaffiliated Stockholders”). A total of 648,219,746 shares of Company Common Stock, representing approximately 74.89% of the voting power of the outstanding shares of the Company’s Common Stock entitled to vote, were present or represented by proxy at the Special Meeting, constituting a quorum to conduct business.

The Special Meeting was held to consider the following proposals:

 

  1.

Merger Agreement Proposal. A proposal to adopt the Merger Agreement, pursuant to which, subject to the terms and conditions set forth therein and among other things, Merger Sub will be merged with and into the Company, with the Company surviving the Merger as a wholly owned subsidiary of Parent (the “Merger Agreement Proposal”).

 

  2.

Adjournment Proposal. A proposal to adjourn the Special Meeting, from time to time, to a later date or dates if necessary or appropriate, including adjournments to solicit additional proxies if there are insufficient votes at the time of the Special Meeting to approve the Merger Agreement Proposal (the “Adjournment Proposal”).

 

  3.

Merger-Related Compensation Proposal. A proposal to approve, by a nonbinding, advisory vote, certain compensation that may become payable to the Company’s named executive officers in connection with the completion of the Merger (the “Merger-Related Compensation Proposal”).

Each proposal is described in detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on June 6, 2025 and first mailed to the Company’s stockholders on June 6, 2025. The Merger Agreement and the Merger-Related Compensation Proposal were each approved by the requisite vote of the Company’s stockholders. The final voting results for each proposal are described below.

The Merger Agreement Proposal

Approval of the proposal to adopt the Merger Agreement required both the affirmative vote of (i) the holders of a majority of the outstanding shares of Company Common Stock entitled to vote on such matter at the Special Meeting (the “Majority of the Outstanding Shares”) and (ii) the holders of a majority of the outstanding shares of Company Common Stock held by the Unaffiliated Stockholders cast on such matter at the Special Meeting (the “Majority of the Unaffiliated Shares Cast”). A total of 500,386,777 shares of Company Common Stock held by the Unaffiliated Stockholders were cast on this matter at the Special Meeting.

 

     For      Against      Abstain  

Majority of the Outstanding Shares

      626,190,387        20,140,186        1,889,173  

Majority of the Unaffiliated Shares Cast

      478,357,418        20,140,186        1,889,173  

The Merger Agreement was approved by the requisite votes of the Company’s stockholders.

 

2

The Merger-Related Compensation Proposal

Approval on a nonbinding advisory basis of the Merger-Related Compensation Proposal required the affirmative vote of a majority of the shares of Company Common Stock present in person or by proxy at the Special Meeting and entitled to vote on the Merger-Related Compensation Proposal.

 

For    Against    Abstain
608,730,038    34,916,603    4,573,105

The Merger-Related Compensation Proposal was approved on a nonbinding advisory basis.

In light of the approval of the Merger Agreement Proposal, the Adjournment Proposal was rendered moot and was not presented at the Special Meeting. There were no recorded broker non-votes.

 

Item 8.01.

Other Events.

On July 11, 2025, the Company issued a press release announcing the preliminary results of the Special Meeting. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated herein by reference.

 

Item 9.01.

Financial Statements and Exhibits.

 

(d)

Exhibits

 

Exhibit

   

Description

99.1    Press Release of Walgreens Boots Alliance, Inc. dated July 11, 2025
104    Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

3

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  WALGREENS BOOTS ALLIANCE, INC.
Date: July 11, 2025     By:  

/s/ Lanesha Minnix

    Name: Lanesha Minnix
    Title:Executive Vice President, Global Chief Legal Officer and Corporate Secretary

 

4

EX-99.1 2 d94027dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO    LOGO

Walgreens Boots Alliance Shareholders Overwhelmingly Approve Transaction with Sycamore

Partners

Transaction expected to close in the third or fourth quarter of calendar year 2025

DEERFIELD, Ill. – July 11, 2025 – Walgreens Boots Alliance, Inc. (Nasdaq: WBA) (the “Company” or “WBA”) today announced that at the Company’s Special Meeting of Shareholders (the “Special Meeting”), WBA shareholders approved the previously announced acquisition of the Company by entities affiliated with Sycamore Partners Management, L.P. (“Sycamore”).

According to the preliminary results, approximately 96% of votes cast at the Special Meeting by all shareholders were voted in favor of the merger agreement proposal. In addition, approximately 95% of the votes cast at the Special Meeting by unaffiliated shareholders were voted in favor of the merger agreement proposal.

“We appreciate the consideration and overwhelming support from our shareholders in our value-maximizing transaction with Sycamore,” said Tim Wentworth, Chief Executive Officer of Walgreens Boots Alliance. “With Sycamore’s partnership, we will be better positioned to accelerate our turnaround strategy, further enhance the customer, patient and team member experience and become the first choice for pharmacy, retail and health services. We look forward to closing the transaction and entering this next chapter.”

As previously announced on March 6, 2025, under the terms of the Merger Agreement, WBA shareholders will receive $11.45 per share in cash at closing, and one non-transferable Divested Asset Proceeds Right to receive up to an additional $3.00 in cash per share from the future monetization of WBA’s debt and equity interests in VillageMD, which includes the Village Medical, Summit Health and CityMD businesses.

WBA expects to close the transaction in the third or fourth quarter of calendar year 2025, subject to customary closing conditions, including the receipt of required regulatory approvals.

The final voting results of the Special Meeting will be reported in a Form 8-K filed by WBA with the U.S. Securities and Exchange Commission.

Advisors

Centerview Partners is acting as financial advisor, Kirkland & Ellis LLP is acting as legal advisor and Ropes & Gray LLP is acting as healthcare regulatory counsel to WBA. Morgan Stanley & Co. LLC was also a financial advisor, and provided a fairness opinion to the WBA Board of Directors.

About Walgreens Boots Alliance

Walgreens Boots Alliance (Nasdaq: WBA) is an integrated healthcare, pharmacy and retail leader serving millions of customers and patients every day, with a 175-year heritage of caring for communities.

A trusted, global innovator in retail pharmacy with approximately 12,500 locations across the U.S., Europe and Latin America, WBA plays a critical role in the healthcare ecosystem. Through dispensing medicines, improving access to pharmacy and health services, providing high quality health and beauty products and offering anytime, anywhere convenience across its digital platforms, WBA is shaping the future of healthcare in the thousands of communities it serves and beyond.

WBA employs approximately 312,000 people, with a presence in eight countries and consumer brands including: Walgreens, Boots, Duane Reade, No7 Beauty Company and Benavides. The Company is proud of its contributions to healthy communities, a healthy planet, an inclusive workplace and a sustainable marketplace. In fiscal 2024, WBA scored 100% on the Disability Equality Index for disability inclusion.

More Company information is available at www.walgreensbootsalliance.com.

(WBA-GEN)

Forward-Looking Statements

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, such as statements regarding our expectations, intentions or strategies regarding the future. In some cases, you can identify forward-looking statements by the use of forward-looking terminology such as “accelerate,” “aim,” “ambition,” “anticipate,” “approximate,” “aspire,” “assume,” “believe,” “can,” “continue,” “could,” “create,” “enable,” “estimate,” “expect,” “extend,” “forecast,” “future,” “goal,” “guidance,” “intend,” “long-term,” “may,” “model,” “ongoing,” “opportunity,” “outlook,” “plan,” “position,” “possible,” “potential,” “predict,” “preliminary,” “project,” “seek,” “should,” “strive,” “target,” “transform,” “trend,” “vision,” “will,” “would,” and variations of these terms or other similar expressions, although not all forward-looking statements contain these words. Such statements include, but are not limited to, statements regarding the proposed transaction, our ability to consummate the proposed transaction on the expected timeline or at all, the anticipated benefits of the proposed transaction, and the terms, the impact of the proposed transaction on our future business, results of operations and financial condition and the scope of the expected financing in connection with the proposed transaction. Forward-looking statements are based on current estimates, assumptions and beliefs and are subject to known and unknown risks and uncertainties, many of which are beyond our control, that may cause actual results to vary materially from those indicated by such forward-looking statements. Such risks and uncertainties include, but are not limited to: (i) the risk that the proposed transaction may not be completed in a timely manner or at all; (ii) the ability of affiliates of Sycamore Partners to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the proposed transaction; (iii) the failure to satisfy any of the conditions to the consummation of the proposed transaction, including the receipt of certain regulatory approvals; (iv) the occurrence of any event, change or other circumstance or condition that could give rise to the

termination of the transaction agreements, including in circumstances requiring the Company to pay a termination fee; (v) the effect of the announcement or pendency of the proposed transaction on the Company’s business relationships, operating results and business generally; (vi) the risk that the proposed transaction disrupts the Company’s current plans and operations; (vii) the Company’s ability to retain and hire key personnel and maintain relationships with key business partners and customers, and others with whom it does business; (viii) risks related to diverting management’s attention from the Company’s ongoing business operations; (ix) significant or unexpected costs, charges or expenses resulting from the proposed transaction; (x) pending and potential litigation relating to the proposed transaction against the parties to the transaction agreements or their respective directors, managers or officers, including the effects of any outcomes related thereto; (xi) uncertainties related to the continued availability of capital and financing and rating agency actions; (xii) certain restrictions during the pendency of the proposed transaction that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; (xiii) uncertainty as to timing of completion of the proposed transaction; (xiv) the risk that the holders of Divested Asset Proceed Rights will receive less-than-anticipated payments or no payments with respect to the Divested Asset Proceed Rights after the closing of the proposed transaction and that such rights will expire valueless; (xv) the impact of adverse general and industry-specific economic and market conditions; (xvi) the possibility that alternative transaction proposals will or will not be made; (xvii) though no such transactions existed, the possibility that, if the Company did not enter into the transaction agreements, it potentially could have, at a later date, attempted to engage in other, unspecified transactions, including restructuring efforts, special dividends or the sale of some or all of the Company’s assets that may have produced a higher aggregate value than that available to the Company’s stockholders in the merger; (xviii) the risk that the Company’s stock price may decline significantly if the merger is not completed and (xviv) other risks, assumptions and uncertainties described in Item 1A (Risk Factors) of our Form 10-K for the fiscal year ended August 31, 2024, as amended and supplemented by those described in Item 1A (Risk Factors) of our Form 10-Q for the fiscal quarter ended May 31, 2025, and in other documents that we file or furnish with the SEC.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions, known or unknown, that could cause actual results to vary materially from those indicated or anticipated. If one or more of these risks or uncertainties materializes, or if underlying assumptions prove incorrect, actual results may vary materially from those indicated or anticipated by such forward-looking statements. All forward-looking statements we make or that are made on our behalf are qualified by these cautionary statements. You should not place undue reliance on forward-looking statements, which speak only as of the date they are made.

We do not undertake, and expressly disclaim, any duty or obligation to update publicly any forward-looking statement after the date of this release, whether as a result of new information, future events, changes in assumptions or otherwise.

Contacts

Media:

Jonathon Hosea

Media@wba.com

Investor Relations:

Brian Holzer

Investor.relations@wba.com

EX-101.SCH 3 wba-20250711.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.DEF 4 wba-20250711_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 wba-20250711_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Document And Entity Information [Table] Document And Entity Information [Table] Document And Entity Information [Line Items] Document And Entity Information [Line Items] Class of Stock [Axis] Class of Stock [Axis] Class of Stock [Domain] Class of Stock [Domain] Common Stock [Member] Common Stock [Member] M 3.600 Walgreens Boots Alliance Inc . Notes Due 20252 [Member] M 3.600 Walgreens Boots Alliance Inc . Notes Due 20252 [Member] M 2.125 Walgreens Boots Alliance Inc . Notes Due 20261 [Member] M 2.125 Walgreens Boots Alliance Inc . Notes Due 20261 [Member] EX-101.PRE 6 wba-20250711_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 7 g94027g0711192925113.jpg GRAPHIC begin 644 g94027g0711192925113.jpg M_]C_X 02D9)1@ ! 0$ 8 !@ #_VP!# @&!@<&!0@'!P<)"0@*#!0-# L+ M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#W^HKBXBM8 M&FF<)&O4FBXN(K6!YIF"QH,DU3"VVN6B22))Y )+V9DME MF@M0<1KN\O:O8'D$UOSZA9WT$NEVUP&N)8FC7*MC.T]3BJIU%1LJDE=Z')"L MZJ>C5N_7T-7SX,O$& D*GE0>_OSC\ZFM[B*Z@2>!P\;C(85RL5OKD$PCNDDFM M&.)%+;\KW]2*VG^R^'+%G1)?LQD&X!L^7GC(SVZ?G7!AZT:T'>+C)=SI]I)- MREI'\O\ @&K145O<17=ND\#AXW&585+6ALFFKH****!A1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %:ZLH;T(L^YHU M.=@. 3[US-O-)=>*5MT9EM8I#MC!PHVYP0/J/UIGVOQ'=:@N$GBM3)_SRVX7 M/KBM?5I4OM,GMM*FAENC@[89%R!N&3UHQ.#E-TXN=E>YQ^VC-.23T_'T-HG MS7%:!9W46LQW-Q;RQ1C<2[H5 ^4]S5>P\/:M#J%OG0Y_I2Q6!C.I"2E?EUT"-64XN3C9K9=S2^U6__/Q% M_P!]BN%UZPO'\22W4%K-)$65E=$+ _*.XJ'_ (1#6?[J_P#?P?XUU]C=V^FV M,%G=SJEQ&N&7K[_UJY3A27,VGL3^E.NM"U1[R::"/*/(S*0Z\@GCO6]83PVEC!;ZE-!%=*"2LLBYQN M.#UKHCRTDW>]SJK1]I:^EG_2+MEI\.GJZ6^Y8F.X1ELA3[=ZM5RB7.OVU\ Z M326X?G]WG(^N*ZNO.HXA5KZ-6[F]/E2M%6L%%9-_X@M].U[3-*GBE#:CO$,P M V!D&2IYSD]JAO/%6GV/BNP\.R[_ +9>QM(A&-J@9P#SU.TXKIY6:7-RBLF7 MQ!;Q^*8/#ZQ2O=26QN6=<;8T!P-W.>3Q5R_O4L-+NKXKYBV\+RE5/WMH)Q^E M*S M450T;54UC0[/5%C,*7,2RA&.=N>V:OT-6=@"BDW+C.X8]A M!^E&X;MN1GTH 6BDR 0"1D]*SM?UF'P]H=UJMQ'))#;J&9(\;CD@<9^M-)MV M0&E17'VGQ MY+ZSMM0T75M,6\<1P3W< $;.>B[@3@GM77D@=2!FG*+CN%Q:* M*9)*L<+RDY55+''H*D!]%9^B:Q;:_H]OJEF)!;W )02##<$CD9/<5?!!&001 M[4VFG9@+17/^*?&&F^$8[-]0\P_:IO+41@$J!U8Y/09'YU/XF\01>&O#\VK/ M UQ'$4&Q& +;F"]?QIJ,G;S%=&S17/-XJ7^U==T^+3[B:;28HI2L6&:;>NX! M1ZUM6MP;BRM[B2)[=I8UIQ_6N]P=!.$NHU7C57M%M$V*X+Q/_P AY_\ @/\ (56_ MX2_6?[R_]^Q_A77V-I;ZE8P7EW CW$BY9NGM_2O*Q^$G6I**?4FEBZ>*?)#I MW-2'_41_[H_E7!^./^0S%C_G@,_FU6+K7=56\FA@DPB2,J@(O !X[5T&GP0W M=A!<:E##+=,""TL:YQN.!THPN-A4J.$4]"L33^L4_9IV-6/_ %:_04ZN-CM/ M$EUJ 9WGBMB^3F7;A<^F:[*NZK34+:I^AO1JNHG[K7JQW%O M%=VTMM.@>&5#&ZGHRD8(_*J-EH&F:=H1T6UM0FGE'C,)8G*MG=DDYYR:<*JC M&W]6-&KGF;:G8:C;>(O$EW92W]MJM[#I=A;K*8?,5,$?/U56(R?I5:.RO/#V MN7]@--ATJVO=$NI)+2"\:=&*J<.=W0]N/>O3AX3T,>'!X?-@C:8,XA9B<$G= MG=G.U4YP4\.W>C1W$_]GQ>*ULHT$S< M0'^#=G.*[/Q3X;4Z;ING6/A*VUFRMD*(LMYY+PXQC#'D@]^>PIOA+P'%9Z') M!K%I#&9-2_M"&U@E8K;D !%W9^;&/I5>TC;F"W0YKQ%I5M:^,K'PS;:#<:AH M]OI[7$.G179C#2-(=SEF.6QZ9_3-07K^(=!^'VK6LMK>6%F]]$EK')<*\D4# MGYD#@\#@#G^]7I^N>%](\1>2=2M?,D@),4J.R.F>N&4@X]J;9^$]$L=&N-(B ML@UEZ+IK))'? MK+>B9)!MRC8R3N!'7_Z]8%KH5C_PJ(^+@)QK\;&1;X7#[]PGVCOCI[5ZCI'@ M?0=#O5N[*UE$Z(41I+B1]BG@@!B0*L)X4T:/PT?#RVI&EG.8?,;NV_[V<]>> MM/VRO]W];ARGGGB?29+?6+SQ'KFCOK&E2)$ZS07K1RV(VC(" COSQ_4UUGQ$ MFCN?AAJ<\3;HY((W0GN"ZD5 N",[B,YQ[&M&RT'3O&7BSQ*WB!9+EK&Y6"V@,S(((]O M# *1R>N:W['X<>%=/O(KJ'2]TT1#1F::20*1T.&8BK.L^"/#^O7IO;ZR)N67 M8\D4KQEU]&VD9_&J]K'9!9GG&GW$^MP>&- U&\GFTB;4+R%Y#*0;A(@#$I8< MD$DC\!Z5KOH&F:?XQO\ PQ:1N=&NM(-U<61FA7 MNBPZ/-IT7V& @PQKE?+/JI!R#R><\YHT3PMH_AT3'3;3RY)\>;([M([XZ LQ M)Q[4.JN@=:W=7'B M+QEK+Q:%=ZMI]I;/I<;0,H$#],9[TU5CHK;6#E9P^LDC6?B402"--M^1_UR-0SP6O MB1M)TN+PXFK7MGI%LTLMS?/!'$K(" O))SUKT2?PUI-Q-JDTML6?5(EBNSY MC#S%4;0.O''IBJ>H^!/#NIBU^T6+![:%;>.2.9T;RU& I(.2/K0JL?Z] Y6> M:61GU?0/#>DZG+++;G6Y;.2/SV.Z-1PI8$%@,X!K4OHSX,UKQ+8>'O-MK5=# M^UI")&<1R[]N]=Q." 2:]!B\*:)!!IL$-BL<6FR^;:JC,-C^IY^8_7-66T33 MWU>75'MPUW-;?99&8DAHLYVE>G7VH=97\O\ @ARG&:5X5T72O"T/B73XGEUA M-/:Y2Z,[L9I#$2F*XK3--U:XT33]8T7PWJ#:T66?\ M8Z@K"<[OF#* M6^Z>1C\^]>IZ=X!\-Z3J<>H65BTO=0@T\1M<[EB<''XUG3DU=)7N93YE.\KU8YC;;OW+V)]*V)=.L[*.34K>WVW$<;2+EFQ MG:>HS7D/GQ-6/*G%Q>M]/ZV*;YW==#1^RV__ #[Q?]\"N&UV^O$\1RVL%U-' M$&551'*@?*.PJ\/%M[G'V:'K_=;_ !K8&E6-PBZK-;;KIHQ*<,V,[>PS7O4E M["7-41A7C[:-J;M8V<8Z5Q#PR7?C![N1&6TBE^:5AA1MXZ^Y7]:+>X\1W=PD MEV\T%FK R,5\O"]\=":Z5C;:[:%4>3[.'&X[<;\W2L*=:-*?*WJT)26* M2=FDG?7J6K2]BO5=X-QC4XWD8!/M5BHX(8[>%88E"QH, "I*S=KZ':KVU"BB MBD,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH *BN;:&\MW@G0/&XY!HHIIM.Z$TFK,BT^R&GVWV=9"\:L2F[JH/;WY MS7+W/VRU\8KS*+629<9U-]9B^@$#N5C+ N . M6 [?GBIH((K:%884"1KT HHK+DCS GRAPHIC 8 g94027g0711192925429.jpg GRAPHIC begin 644 g94027g0711192925429.jpg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htm IDEA: XBRL DOCUMENT v3.25.2
Document and Entity Information
Jul. 11, 2025
Document And Entity Information [Line Items]  
Amendment Flag false
Entity Central Index Key 0001618921
Document Type 8-K
Document Period End Date Jul. 11, 2025
Entity Registrant Name WALGREENS BOOTS ALLIANCE, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-36759
Entity Tax Identification Number 47-1758322
Entity Address, Address Line One 108 Wilmot Road
Entity Address, City or Town Deerfield
Entity Address, State or Province IL
Entity Address, Postal Zip Code 60015
City Area Code (847)
Local Phone Number 315-3700
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Common Stock [Member]  
Document And Entity Information [Line Items]  
Security 12b Title Common Stock, $0.01 par value
Trading Symbol WBA
Security Exchange Name NASDAQ
M 3.600 Walgreens Boots Alliance Inc . Notes Due 20252 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 3.600% Walgreens Boots Alliance, Inc. notes due 2025
Trading Symbol WBA25
Security Exchange Name NASDAQ
M 2.125 Walgreens Boots Alliance Inc . Notes Due 20261 [Member]  
Document And Entity Information [Line Items]  
Security 12b Title 2.125% Walgreens Boots Alliance, Inc. notes due 2026
Trading Symbol WBA26
Security Exchange Name NASDAQ
XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.2 html 4 22 1 false 3 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d94027d8k.htm wba-20250711.xsd wba-20250711_def.xml wba-20250711_lab.xml wba-20250711_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d94027d8k.htm": { "nsprefix": "wba", "nsuri": "http://walgreensbootsalliance.com/20250711", "dts": { "inline": { "local": [ "d94027d8k.htm" ] }, "schema": { "local": [ "wba-20250711.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/naics/2024/naics-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "wba-20250711_def.xml" ] }, "labelLink": { "local": [ "wba-20250711_lab.xml" ] }, "presentationLink": { "local": [ "wba-20250711_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 2, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 4, "entityCount": 1, "segmentCount": 3, "elementCount": 30, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 28 }, "report": { "R1": { "role": "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2025-07-11_to_2025-07-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d94027d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2025-07-11_to_2025-07-11", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d94027d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockDomain", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "wba_DocumentAndEntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://walgreensbootsalliance.com/20250711", "localname": "DocumentAndEntityInformationLineItems", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Line Items]", "terseLabel": "Document And Entity Information [Line Items]" } } }, "auth_ref": [] }, "wba_DocumentAndEntityInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://walgreensbootsalliance.com/20250711", "localname": "DocumentAndEntityInformationTable", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document And Entity Information [Table]", "terseLabel": "Document And Entity Information [Table]" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "wba_M2.125WalgreensBootsAllianceInc.NotesDue20261Member": { "xbrltype": "domainItemType", "nsuri": "http://walgreensbootsalliance.com/20250711", "localname": "M2.125WalgreensBootsAllianceInc.NotesDue20261Member", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 20261 [Member]", "terseLabel": "M 2.125 Walgreens Boots Alliance Inc . Notes Due 20261 [Member]" } } }, "auth_ref": [] }, "wba_M3.600WalgreensBootsAllianceInc.NotesDue20252Member": { "xbrltype": "domainItemType", "nsuri": "http://walgreensbootsalliance.com/20250711", "localname": "M3.600WalgreensBootsAllianceInc.NotesDue20252Member", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 20252 [Member]", "terseLabel": "M 3.600 Walgreens Boots Alliance Inc . Notes Due 20252 [Member]" } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "us-gaap_StatementClassOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementClassOfStockAxis", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://walgreensbootsalliance.com//20250711/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 17 0001193125-25-158216-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-25-158216-xbrl.zip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d94027d8k_htm.xml IDEA: XBRL DOCUMENT 0001618921 2025-07-11 2025-07-11 0001618921 us-gaap:CommonStockMember 2025-07-11 2025-07-11 0001618921 wba:M3.600WalgreensBootsAllianceInc.NotesDue20252Member 2025-07-11 2025-07-11 0001618921 wba:M2.125WalgreensBootsAllianceInc.NotesDue20261Member 2025-07-11 2025-07-11 false 0001618921 8-K 2025-07-11 WALGREENS BOOTS ALLIANCE, INC. DE 001-36759 47-1758322 108 Wilmot Road Deerfield IL 60015 (847) 315-3700 false false false false Common Stock, $0.01 par value WBA NASDAQ 3.600% Walgreens Boots Alliance, Inc. notes due 2025 WBA25 NASDAQ 2.125% Walgreens Boots Alliance, Inc. notes due 2026 WBA26 NASDAQ false